Ironwood Pharmaceuticals (IRWD) Research & Development (2016 - 2025)
Ironwood Pharmaceuticals (IRWD) has disclosed Research & Development for 16 consecutive years, with $21.9 million as the latest value for Q4 2025.
- Quarterly Research & Development fell 13.89% to $21.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $95.1 million through Dec 2025, down 14.62% year-over-year, with the annual reading at $95.1 million for FY2025, 14.62% down from the prior year.
- Research & Development hit $21.9 million in Q4 2025 for Ironwood Pharmaceuticals, down from $22.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $35.7 million in Q4 2023 to a low of $6.0 million in Q2 2023.
- Historically, Research & Development has averaged $20.4 million across 5 years, with a median of $22.2 million in 2025.
- Biggest five-year swings in Research & Development: tumbled 67.2% in 2022 and later surged 406.47% in 2024.
- Year by year, Research & Development stood at $31.9 million in 2021, then tumbled by 67.2% to $10.4 million in 2022, then soared by 241.53% to $35.7 million in 2023, then dropped by 28.83% to $25.4 million in 2024, then dropped by 13.89% to $21.9 million in 2025.
- Business Quant data shows Research & Development for IRWD at $21.9 million in Q4 2025, $22.5 million in Q3 2025, and $23.4 million in Q2 2025.